SE0101697D0 - Pharmaceutical combination - Google Patents
Pharmaceutical combinationInfo
- Publication number
- SE0101697D0 SE0101697D0 SE0101697A SE0101697A SE0101697D0 SE 0101697 D0 SE0101697 D0 SE 0101697D0 SE 0101697 A SE0101697 A SE 0101697A SE 0101697 A SE0101697 A SE 0101697A SE 0101697 D0 SE0101697 D0 SE 0101697D0
- Authority
- SE
- Sweden
- Prior art keywords
- androgen
- relates
- erbeta
- optionally
- pharmaceutical product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101697A SE0101697D0 (sv) | 2001-05-14 | 2001-05-14 | Pharmaceutical combination |
JP2002589045A JP2004529182A (ja) | 2001-05-14 | 2002-05-08 | 医薬組成物 |
EP02730415A EP1395286A2 (en) | 2001-05-14 | 2002-05-08 | Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
PCT/GB2002/002125 WO2002092129A2 (en) | 2001-05-14 | 2002-05-08 | Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
AU2002302737A AU2002302737A1 (en) | 2001-05-14 | 2002-05-08 | Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
US10/477,242 US20040204390A1 (en) | 2001-05-14 | 2002-05-08 | Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101697A SE0101697D0 (sv) | 2001-05-14 | 2001-05-14 | Pharmaceutical combination |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0101697D0 true SE0101697D0 (sv) | 2001-05-14 |
Family
ID=20284106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0101697A SE0101697D0 (sv) | 2001-05-14 | 2001-05-14 | Pharmaceutical combination |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040204390A1 (sv) |
EP (1) | EP1395286A2 (sv) |
JP (1) | JP2004529182A (sv) |
AU (1) | AU2002302737A1 (sv) |
SE (1) | SE0101697D0 (sv) |
WO (1) | WO2002092129A2 (sv) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
WO2014130932A2 (en) * | 2013-02-25 | 2014-08-28 | Novartis Ag | Novel androgen receptor mutation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
WO1998048790A1 (en) * | 1997-04-28 | 1998-11-05 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
HUP0003194A3 (en) * | 1997-08-15 | 2003-03-28 | Cephalon Inc West Chester | Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer |
JP3270030B2 (ja) * | 1999-10-12 | 2002-04-02 | 株式会社ファンケル | 食品組成物 |
GB2361642A (en) * | 2000-10-24 | 2001-10-31 | Karobio Ab | Estrogen receptor beta (ERbeta) agonists for use in cancer treatment |
-
2001
- 2001-05-14 SE SE0101697A patent/SE0101697D0/sv unknown
-
2002
- 2002-05-08 AU AU2002302737A patent/AU2002302737A1/en not_active Abandoned
- 2002-05-08 WO PCT/GB2002/002125 patent/WO2002092129A2/en not_active Application Discontinuation
- 2002-05-08 US US10/477,242 patent/US20040204390A1/en not_active Abandoned
- 2002-05-08 JP JP2002589045A patent/JP2004529182A/ja not_active Withdrawn
- 2002-05-08 EP EP02730415A patent/EP1395286A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2004529182A (ja) | 2004-09-24 |
WO2002092129A2 (en) | 2002-11-21 |
US20040204390A1 (en) | 2004-10-14 |
AU2002302737A1 (en) | 2002-11-25 |
WO2002092129A3 (en) | 2003-02-27 |
EP1395286A2 (en) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
SE0100568D0 (sv) | Compounds | |
IS6647A (is) | Kínasólínafleiður til að meðhöndla æxli | |
CY1110521T1 (el) | Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας | |
EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
ATE388167T1 (de) | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 | |
AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
IL162348A (en) | Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer | |
HK1078466A1 (en) | Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance | |
GB0121490D0 (en) | Ciompounds | |
ZA200205191B (en) | LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer. | |
CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
MY137435A (en) | Retinoid compounds (i) | |
HUP0202253A2 (hu) | Szelektív iGluR5-receptorantagonisták a migrén kezelésére | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
SE0100566D0 (sv) | Compounds | |
TR200402230T4 (tr) | O-ikameli 6-metil-tramadol-türevleri | |
SE0101697D0 (sv) | Pharmaceutical combination | |
GB0121494D0 (en) | Compounds | |
PT1255538E (pt) | Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros | |
DE60226319D1 (de) | Verbindungen die ein an einen vektor gebundenes analgetisches molekül enthalten | |
WO2002092565A3 (en) | 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists | |
DK1420789T3 (da) | Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling | |
DE60001336D1 (de) | Antiseptisches/fungizides Mittel und endermatische Salbe, die es enthalten |